期刊文献+

替比夫定与阿德福韦酯治疗乙型肝炎肝硬化疗效 被引量:4

Comparison of Curative Effects of Tlbivudine and Adefovir Dipivoxil in Treating Hepatitis B Cirrhosis
下载PDF
导出
摘要 目的:比较替比夫定(LDT)与阿德福韦酯(ADV)治疗乙型肝炎肝硬化的临床效果。方法:将120例乙型肝炎肝硬化患者随机分成LDT组和ADV组,两组在采用常规保肝对症治疗的基础上分别用LDT及ADV治疗,疗程均为96周;观察治疗前及治疗后12、48、96周时两组患者的病毒学指标、丙氨酸氨基转移酶(ALT)、总胆红素(TBil)、白蛋白(ALB)、肌酐(cr)、尿素氮(BUN)、凝血酶原时间(PT)、外周血T淋巴细胞亚群及ChildPugh分级。结果:治疗12、48、96周时,LDT组HBV-DNA阴转率分别为50%、60%、80%,明显高于ADV组(分别为13%、40%、60%),差异有统计学意义(P<0.05);治疗48和96周时LDT组患者血清HBeAg阴转率(分别为40%、47%)及HBeAg/抗HBe转换率(25%、30%)明显高于ADV组(HBeAg阴转率为18.3%、25%,HBeAg/抗HBe转换率为10%、15%),差异有统计学意义(P<0.05);在治疗96周时,LDT组ALT、TBil、PT、cr、BUN明显低于ADV组,ALB、CD4+及CD4+/CD8+比值明显高于ADV组(P<0.05);Child-Pugh分级改善,与ADV组比较差异有统计学意义(P<0.05)。结论:替比夫定治疗乙型肝炎肝硬化与阿德福韦酯比较、能更有效抑制病毒复制,改善肝、肾功能、凝血指标及Child-Pugh分级,并能提高患者免疫功能。 Objective: To compare the clinical efficacy of telbivudine (LDT) and adefovir dipivoxil (ADV) in treating hepatitis B cirrhosis. Methods: A total of 120 patients with hepatitis B cirrhosis were randomly divided into group LDT and group ADV. Besides of conventional treatment, patients in the two groups were given LDT and ADV for 96weeks respectively. Virological indicators, serum levels of alanine aminotransferase ( ALT), total bilirubin ( TBil), albumin ( ALB ), creatinine ( cr), urea ni- trogen (BUN) and prothrombin time (PT), and T lymphocyte subsets in peripheral blood and Child- Pugh grading of patients in the two groups were detected before treatment and in 12,48 and 96 weeks after treatment. Results: In 12,48 and 96 weeks after treatment, the HBV-DNA negative conversion rates of group LDT were 50%, 60%, and 80%, which were significantly higher than those of group ADV (13%, 40%, and 60% respectively) (P 〈 0. 05) . In 48 and 96 weeks after treatment, HBeAg negative conversion rates of group LDT were 40%, and 47%, which were significantly higher than those of group ADV ( 18.3% , 25% ) respectively, and HBeAg/anti-HBe conversion rates ofgroup LDT were 25%, 30%, which were higher than those of group ADV (respectively 10%, 15% ), and the difference was statistically significant (P 〈 0.05 ) . In 96 week after treatment, in group LDT, the ALT, TBiL, PT and cr levels were significantly lower than in group ADV, and ALB level, CD4 + cell counts, and CD4 +/CD8+ cell ratio were significantly higher than in group ADV (P 〈 0.05 ) ; The Child-Pugh grading in group LDT were improved after treatment ( P 〈 0.05 ), compared with group ADV. Conclusions: Compared with ADV, LDT can more effectively inhibit virus liver function, kidney function, prothrombin time, Child-Pugh grading and immune copy and improve function.
出处 《贵阳医学院学报》 CAS 2014年第3期392-396,共5页 Journal of Guiyang Medical College
关键词 替比夫定 阿德福韦酯 肝炎 乙型 肝硬化 肝功能试验 病毒学指标 淋巴细胞亚群 telbivudine adefovir dipivoxil hepatitis B liver cirrhosis live fuction tset virologicalindicators lymphocyte subsets
  • 相关文献

参考文献18

  • 1罗生强.替比夫定治疗慢性乙型肝炎的新进展[J].中国新药杂志,2008,17(8):625-629. 被引量:36
  • 2Nash K. Telbivudine in the treatment of chronic hepatitis B[J]. Adv Ther, 2009(2) :155 -169.
  • 3贾继东,李兰娟.慢性乙型肝炎防治指南(2010年版)[J].中华肝脏病杂志,2011,19(1):13-24. 被引量:3212
  • 4Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine inpatients with chronic hepatitis B [ J]. N Engl J Med, 2007(25) :2576 -2588.
  • 5Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivu- dine in Chinesepatients with chronic hepatitis B:resuhs at 1 year of a randomized,double-blind triM[ J]. Hepatology, 2008 (4) :1425.
  • 6Liaw YF, Gane E, Leung N, et al. 2 - Year GLOBE trial re- sults:telbivudine is superior to lamivudine in patients with chronic hepatitisB [ J ]. Gastroenterology, 2009 (2) : 389 - 392.
  • 7Suzuki F. Markers of hepatitis B virus and clinical signifi- cances[ J]. Nihon Rinsho, 2011 (Suppl 4) :385 - 389.
  • 8Fried MW , Piratvisuth T, Lau GK, et al. HBeAg and hepa- titis B virus DNA as outcome predictors during therapy with peginterferon alfa - 2a for HBeAg - positive chronic hepatitis B [ J ]. Hepatology, 2008 (2) :428 - 434.
  • 9Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B vi- rus surface antigen levels:a guide to sustained response to peginterforon alfa- 2a in HBeAg- negative chronic hepa- titis B[J]. Hepatology, 2009(4) :1141 -1150.
  • 10Moueari R, Mackiewicz V, Lada O, et al. Early serum HB- sag drop:a strong predictor of sustained virological re- sponse to pegylated interferon alfa- 2a in HBeAg- nega- tive patients[ J]. Hepatology, 2009(4) : 1151 - 1157.

二级参考文献71

共引文献3305

同被引文献45

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部